Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial
Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children...
Gespeichert in:
| Veröffentlicht in: | Journal of autism and developmental disorders 2011-02, Vol.41 (2), p.175-184 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 184 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | Journal of autism and developmental disorders |
| container_volume | 41 |
| creator | Wright, Barry Sims, David Smart, Siobhan Alwazeer, Ahmed Alderson-Day, Ben Allgar, Victoria Whitton, Clare Tomlinson, Heather Bennett, Sophie Jardine, Jenni McCaffrey, Nicola Leyland, Charlotte Jakeman, Christine Miles, Jeremy |
| description | Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms. |
| doi_str_mv | 10.1007/s10803-010-1036-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_954617025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A342765519</galeid><ericid>EJ912256</ericid><sourcerecordid>A342765519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-e55d2a61fd7c51bf81e8610ad5154d1298e528f69a6a32582749b5c993beb0363</originalsourceid><addsrcrecordid>eNqFkt9v0zAQxyMEYmXwByAhZA0hxEOGf8RJzFupBgxtMK2D18hJLq0nxy62M-Av49_DWcumoqLJD7bvPnc-f--S5CnBhwTj4o0nuMQsxQSnBLM85feSCeEFS1nG6P1kgklOU0Z5sZc88v4SYyxKSh8mexRzxjkTk-T3KWgZrFEGfQPnB4_OtGygtihaZkulWwcG_VBhiaZDUL5H8xU0wQ09mlnTqqCs8UiaFs3hChyguQZYoTNnaw29R59tQNMejIxXFCx6B0t5pezg0Kk0cgHRFdA8OBlgocC_RVN0HrPZXnloxyeCs1qPR2e9t_EJdOGU1I-TB53UHp5s9v3k6_uji9nH9OTLh-PZ9CRtcpqFFDhvqcxJ1xYNJ3VXEihzgmXLCc9aQkUJnJZdLmQuo1AlLTJR80YIVkMdJWX7yat13pWz3wfwoYqVNaC1NGAHXwme5aTAlN9JlpyL2IEsu5vMeJFnnNJIHvxDXkbpTPxwhFhGseBjiS_W0EJqqJTpbJSzGVNW08gUOedERCrdQS3AgJPaGuhUNG_xhzv4uFroVbMz4PVWQGQC_AwLOXhfHc_Pt1myZpuxqw66auVUL92viuBqHO1qPdoVvr6zvBr1fb7RYqh7aG8i_s5yBF5uAOkbqTsnTaP8LcfKjFJRRO7ZmgOnmhv30SdBKL2Wk67dPrrMAtyt5v8v7g9oNRfU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>843420956</pqid></control><display><type>article</type><title>Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial</title><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>EBSCOhost Education Source</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wright, Barry ; Sims, David ; Smart, Siobhan ; Alwazeer, Ahmed ; Alderson-Day, Ben ; Allgar, Victoria ; Whitton, Clare ; Tomlinson, Heather ; Bennett, Sophie ; Jardine, Jenni ; McCaffrey, Nicola ; Leyland, Charlotte ; Jakeman, Christine ; Miles, Jeremy</creator><creatorcontrib>Wright, Barry ; Sims, David ; Smart, Siobhan ; Alwazeer, Ahmed ; Alderson-Day, Ben ; Allgar, Victoria ; Whitton, Clare ; Tomlinson, Heather ; Bennett, Sophie ; Jardine, Jenni ; McCaffrey, Nicola ; Leyland, Charlotte ; Jakeman, Christine ; Miles, Jeremy</creatorcontrib><description>Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.</description><identifier>ISSN: 0162-3257</identifier><identifier>EISSN: 1573-3432</identifier><identifier>DOI: 10.1007/s10803-010-1036-5</identifier><identifier>PMID: 20535539</identifier><identifier>CODEN: JADDDQ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adolescent ; Autism ; Autism Spectrum Disorders ; Autistic children ; Behavior Modification ; Behavior Problems ; Behavior therapy. Cognitive therapy ; Behavioral Science and Psychology ; Behaviour management ; Biological and medical sciences ; Central Nervous System Depressants - therapeutic use ; Child ; Child and School Psychology ; Child Development Disorders, Pervasive - complications ; Child, Preschool ; Comparative Analysis ; Cross-Over Studies ; Crossover trials ; Developmental Delays ; Double-Blind Method ; Drug Therapy ; Female ; Humans ; Hypnotics. Sedatives ; Male ; Medical sciences ; Melatonin ; Melatonin - therapeutic use ; Neuropharmacology ; Neurosciences ; Original Paper ; Pediatrics ; Pervasive Developmental Disorders ; Pharmacology. Drug treatments ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Public Health ; Side effects ; Sleep ; Sleep disorders ; Sleep Wake Disorders - complications ; Sleep Wake Disorders - drug therapy ; Strategic planning (Business) ; Surveys and Questionnaires ; Symptoms (Individual Disorders) ; Treatment Outcome ; Treatments</subject><ispartof>Journal of autism and developmental disorders, 2011-02, Vol.41 (2), p.175-184</ispartof><rights>Springer Science+Business Media, LLC 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c624t-e55d2a61fd7c51bf81e8610ad5154d1298e528f69a6a32582749b5c993beb0363</citedby><cites>FETCH-LOGICAL-c624t-e55d2a61fd7c51bf81e8610ad5154d1298e528f69a6a32582749b5c993beb0363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10803-010-1036-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10803-010-1036-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,12846,27924,27925,30999,31000,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://eric.ed.gov/ERICWebPortal/detail?accno=EJ912256$$DView record in ERIC$$Hfree_for_read</backlink><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23842297$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20535539$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wright, Barry</creatorcontrib><creatorcontrib>Sims, David</creatorcontrib><creatorcontrib>Smart, Siobhan</creatorcontrib><creatorcontrib>Alwazeer, Ahmed</creatorcontrib><creatorcontrib>Alderson-Day, Ben</creatorcontrib><creatorcontrib>Allgar, Victoria</creatorcontrib><creatorcontrib>Whitton, Clare</creatorcontrib><creatorcontrib>Tomlinson, Heather</creatorcontrib><creatorcontrib>Bennett, Sophie</creatorcontrib><creatorcontrib>Jardine, Jenni</creatorcontrib><creatorcontrib>McCaffrey, Nicola</creatorcontrib><creatorcontrib>Leyland, Charlotte</creatorcontrib><creatorcontrib>Jakeman, Christine</creatorcontrib><creatorcontrib>Miles, Jeremy</creatorcontrib><title>Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial</title><title>Journal of autism and developmental disorders</title><addtitle>J Autism Dev Disord</addtitle><addtitle>J Autism Dev Disord</addtitle><description>Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.</description><subject>Adolescent</subject><subject>Autism</subject><subject>Autism Spectrum Disorders</subject><subject>Autistic children</subject><subject>Behavior Modification</subject><subject>Behavior Problems</subject><subject>Behavior therapy. Cognitive therapy</subject><subject>Behavioral Science and Psychology</subject><subject>Behaviour management</subject><subject>Biological and medical sciences</subject><subject>Central Nervous System Depressants - therapeutic use</subject><subject>Child</subject><subject>Child and School Psychology</subject><subject>Child Development Disorders, Pervasive - complications</subject><subject>Child, Preschool</subject><subject>Comparative Analysis</subject><subject>Cross-Over Studies</subject><subject>Crossover trials</subject><subject>Developmental Delays</subject><subject>Double-Blind Method</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hypnotics. Sedatives</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melatonin</subject><subject>Melatonin - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Neurosciences</subject><subject>Original Paper</subject><subject>Pediatrics</subject><subject>Pervasive Developmental Disorders</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Public Health</subject><subject>Side effects</subject><subject>Sleep</subject><subject>Sleep disorders</subject><subject>Sleep Wake Disorders - complications</subject><subject>Sleep Wake Disorders - drug therapy</subject><subject>Strategic planning (Business)</subject><subject>Surveys and Questionnaires</subject><subject>Symptoms (Individual Disorders)</subject><subject>Treatment Outcome</subject><subject>Treatments</subject><issn>0162-3257</issn><issn>1573-3432</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkt9v0zAQxyMEYmXwByAhZA0hxEOGf8RJzFupBgxtMK2D18hJLq0nxy62M-Av49_DWcumoqLJD7bvPnc-f--S5CnBhwTj4o0nuMQsxQSnBLM85feSCeEFS1nG6P1kgklOU0Z5sZc88v4SYyxKSh8mexRzxjkTk-T3KWgZrFEGfQPnB4_OtGygtihaZkulWwcG_VBhiaZDUL5H8xU0wQ09mlnTqqCs8UiaFs3hChyguQZYoTNnaw29R59tQNMejIxXFCx6B0t5pezg0Kk0cgHRFdA8OBlgocC_RVN0HrPZXnloxyeCs1qPR2e9t_EJdOGU1I-TB53UHp5s9v3k6_uji9nH9OTLh-PZ9CRtcpqFFDhvqcxJ1xYNJ3VXEihzgmXLCc9aQkUJnJZdLmQuo1AlLTJR80YIVkMdJWX7yat13pWz3wfwoYqVNaC1NGAHXwme5aTAlN9JlpyL2IEsu5vMeJFnnNJIHvxDXkbpTPxwhFhGseBjiS_W0EJqqJTpbJSzGVNW08gUOedERCrdQS3AgJPaGuhUNG_xhzv4uFroVbMz4PVWQGQC_AwLOXhfHc_Pt1myZpuxqw66auVUL92viuBqHO1qPdoVvr6zvBr1fb7RYqh7aG8i_s5yBF5uAOkbqTsnTaP8LcfKjFJRRO7ZmgOnmhv30SdBKL2Wk67dPrrMAtyt5v8v7g9oNRfU</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Wright, Barry</creator><creator>Sims, David</creator><creator>Smart, Siobhan</creator><creator>Alwazeer, Ahmed</creator><creator>Alderson-Day, Ben</creator><creator>Allgar, Victoria</creator><creator>Whitton, Clare</creator><creator>Tomlinson, Heather</creator><creator>Bennett, Sophie</creator><creator>Jardine, Jenni</creator><creator>McCaffrey, Nicola</creator><creator>Leyland, Charlotte</creator><creator>Jakeman, Christine</creator><creator>Miles, Jeremy</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>7SW</scope><scope>BJH</scope><scope>BNH</scope><scope>BNI</scope><scope>BNJ</scope><scope>BNO</scope><scope>ERI</scope><scope>PET</scope><scope>REK</scope><scope>WWN</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88G</scope><scope>88J</scope><scope>8A4</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial</title><author>Wright, Barry ; Sims, David ; Smart, Siobhan ; Alwazeer, Ahmed ; Alderson-Day, Ben ; Allgar, Victoria ; Whitton, Clare ; Tomlinson, Heather ; Bennett, Sophie ; Jardine, Jenni ; McCaffrey, Nicola ; Leyland, Charlotte ; Jakeman, Christine ; Miles, Jeremy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-e55d2a61fd7c51bf81e8610ad5154d1298e528f69a6a32582749b5c993beb0363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Autism</topic><topic>Autism Spectrum Disorders</topic><topic>Autistic children</topic><topic>Behavior Modification</topic><topic>Behavior Problems</topic><topic>Behavior therapy. Cognitive therapy</topic><topic>Behavioral Science and Psychology</topic><topic>Behaviour management</topic><topic>Biological and medical sciences</topic><topic>Central Nervous System Depressants - therapeutic use</topic><topic>Child</topic><topic>Child and School Psychology</topic><topic>Child Development Disorders, Pervasive - complications</topic><topic>Child, Preschool</topic><topic>Comparative Analysis</topic><topic>Cross-Over Studies</topic><topic>Crossover trials</topic><topic>Developmental Delays</topic><topic>Double-Blind Method</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hypnotics. Sedatives</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melatonin</topic><topic>Melatonin - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Neurosciences</topic><topic>Original Paper</topic><topic>Pediatrics</topic><topic>Pervasive Developmental Disorders</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Public Health</topic><topic>Side effects</topic><topic>Sleep</topic><topic>Sleep disorders</topic><topic>Sleep Wake Disorders - complications</topic><topic>Sleep Wake Disorders - drug therapy</topic><topic>Strategic planning (Business)</topic><topic>Surveys and Questionnaires</topic><topic>Symptoms (Individual Disorders)</topic><topic>Treatment Outcome</topic><topic>Treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wright, Barry</creatorcontrib><creatorcontrib>Sims, David</creatorcontrib><creatorcontrib>Smart, Siobhan</creatorcontrib><creatorcontrib>Alwazeer, Ahmed</creatorcontrib><creatorcontrib>Alderson-Day, Ben</creatorcontrib><creatorcontrib>Allgar, Victoria</creatorcontrib><creatorcontrib>Whitton, Clare</creatorcontrib><creatorcontrib>Tomlinson, Heather</creatorcontrib><creatorcontrib>Bennett, Sophie</creatorcontrib><creatorcontrib>Jardine, Jenni</creatorcontrib><creatorcontrib>McCaffrey, Nicola</creatorcontrib><creatorcontrib>Leyland, Charlotte</creatorcontrib><creatorcontrib>Jakeman, Christine</creatorcontrib><creatorcontrib>Miles, Jeremy</creatorcontrib><collection>ERIC</collection><collection>ERIC (Ovid)</collection><collection>ERIC</collection><collection>ERIC</collection><collection>ERIC (Legacy Platform)</collection><collection>ERIC( SilverPlatter )</collection><collection>ERIC</collection><collection>ERIC PlusText (Legacy Platform)</collection><collection>Education Resources Information Center (ERIC)</collection><collection>ERIC</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Education Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of autism and developmental disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wright, Barry</au><au>Sims, David</au><au>Smart, Siobhan</au><au>Alwazeer, Ahmed</au><au>Alderson-Day, Ben</au><au>Allgar, Victoria</au><au>Whitton, Clare</au><au>Tomlinson, Heather</au><au>Bennett, Sophie</au><au>Jardine, Jenni</au><au>McCaffrey, Nicola</au><au>Leyland, Charlotte</au><au>Jakeman, Christine</au><au>Miles, Jeremy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><ericid>EJ912256</ericid><atitle>Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial</atitle><jtitle>Journal of autism and developmental disorders</jtitle><stitle>J Autism Dev Disord</stitle><addtitle>J Autism Dev Disord</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>41</volume><issue>2</issue><spage>175</spage><epage>184</epage><pages>175-184</pages><issn>0162-3257</issn><eissn>1573-3432</eissn><coden>JADDDQ</coden><abstract>Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20535539</pmid><doi>10.1007/s10803-010-1036-5</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0162-3257 |
| ispartof | Journal of autism and developmental disorders, 2011-02, Vol.41 (2), p.175-184 |
| issn | 0162-3257 1573-3432 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954617025 |
| source | MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); EBSCOhost Education Source; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Autism Autism Spectrum Disorders Autistic children Behavior Modification Behavior Problems Behavior therapy. Cognitive therapy Behavioral Science and Psychology Behaviour management Biological and medical sciences Central Nervous System Depressants - therapeutic use Child Child and School Psychology Child Development Disorders, Pervasive - complications Child, Preschool Comparative Analysis Cross-Over Studies Crossover trials Developmental Delays Double-Blind Method Drug Therapy Female Humans Hypnotics. Sedatives Male Medical sciences Melatonin Melatonin - therapeutic use Neuropharmacology Neurosciences Original Paper Pediatrics Pervasive Developmental Disorders Pharmacology. Drug treatments Psychology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Public Health Side effects Sleep Sleep disorders Sleep Wake Disorders - complications Sleep Wake Disorders - drug therapy Strategic planning (Business) Surveys and Questionnaires Symptoms (Individual Disorders) Treatment Outcome Treatments |
| title | Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A19%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melatonin%20Versus%20Placebo%20in%20Children%20with%20Autism%20Spectrum%20Conditions%20and%20Severe%20Sleep%20Problems%20Not%20Amenable%20to%20Behaviour%20Management%20Strategies:%20A%20Randomised%20Controlled%20Crossover%20Trial&rft.jtitle=Journal%20of%20autism%20and%20developmental%20disorders&rft.au=Wright,%20Barry&rft.date=2011-02-01&rft.volume=41&rft.issue=2&rft.spage=175&rft.epage=184&rft.pages=175-184&rft.issn=0162-3257&rft.eissn=1573-3432&rft.coden=JADDDQ&rft_id=info:doi/10.1007/s10803-010-1036-5&rft_dat=%3Cgale_proqu%3EA342765519%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=843420956&rft_id=info:pmid/20535539&rft_galeid=A342765519&rft_ericid=EJ912256&rfr_iscdi=true |